Loading…
Loading…
BINP (Bionoid Pharma, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
BINP does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BINP and 80,000+ other tickers.
See exactly how BINP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BINP and 80,000+ other tickers.
Bionoid Pharma, Inc. functions as a medical technology enterprise. This company concentrates on the creation and commercialization of advanced medical instruments and solutions, primarily targeting the orthopedic and pain management industries. Founded on October 20, 1997, its corporate headquarters are situated in Beverly Hills, California.
NEW YORK CITY, NEW YORK / ACCESS Newswire / August 12, 2025 / AI Maverick Intel Inc. (OTCID:BINP), a technology-driven innovator focused on redefining how businesses acquire and engage customers through artificial intelligence, today provided a corporate update. On July 30, 2025, the Company announced its selection of IBN, a leading multi-channel financial news and publishing platform serving both private and public companies, to direct AI Maverick Intel's corporate communications.
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / AI Maverick Intel Inc. (OTC:BINP), a technology-forward company focused on transforming how businesses acquire and engage customers through artificial intelligence, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. AI Maverick Intel delivers human-like, AI-powered prospecting through its proprietary platform, enabling intelligent engagement across sectors including healthcare, biotech, insurance, and transportation.
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 17, 2025 / AI Maverick Intel, Inc. (OTCID:BINP) ("AI Maverick" or the "Company") today announces the full rollout of its next-generation prospecting engine-enabling revenue teams to research, engage, and qualify prospects at scale without the need for additional headcount. Key Capabilities Comprehensive contact intelligence - Millions of structured and unstructured data points are aggregated into unified profiles, surfacing job changes, buying signals, and personal preferences in real time.
Company Has Initiated FINRA Process to Complete Rebranding and Ticker Update NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bionoid Pharma, Inc. (OTC PINK:BINP) ("Bionoid" or the "Company") is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company's formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets.
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 16, 2025 / Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors.